HomeSectorLife SciencesSwitzerland: Pinova Capital invests in Ideal-tek’s next stage of growth

Switzerland: Pinova Capital invests in Ideal-tek’s next stage of growth

-

Funds managed by Germany-based Pinova Capital, an independent private equity firm investing in industrial tech companies in the German-speaking region have acquired a stake in Ideal-tek, a Switzerland-based manufacturer of precision tools used in the production of medical devices, as well as in the aerospace and defence industry, and in electronics manufacturing. Ideal-tek is the first investment of Pinova Fund 4.

With a history spanning over 60 years, Ideal-tek is one of the leading providers in its niche and supplies customers in 45 countries through a network of distribution partners.

“For the next phase of growth at Ideal-tek, I looked for the right partner and found it in Pinova, “said managing partner Sandro Grisoni. “What convinced me most was Pinova’s many years of experience in the internationalisation of mid-sized companies.”

Grisoni will remain closely involved with the company as CEO.

“We are very much looking forward to . . . shaping the next phase of growth, in particular the further expansion of [its] international presence in North America and through targeted acquisitions,” said Martin Olbort, managing director and founder at Pinova.

The Pinova deal team (Olbort, Lizzy-Lorenza Nottmeier, Ron Diekämper) was advised by Singular Group (Commercial), BDO Schweiz (Financial & Tax), and CMS (Legal).

Ideal-tek was advised by Tonella and btc.legal sa.

Nick Herbert
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Related Articles
More From Author

Advertisement

Related Resources

Related Events